Yelp (YELP) Received $58.0000 Target From B.Riley FBR; Heat Biologics (HTBX) Sentiment Is 1

May 20, 2018 - By Clifton Ray

Yelp Inc. (NYSE:YELP) Logo

New York-listed Yelp Inc (NYSE:YELP), was raised by equity analysts at B.Riley FBR. B.Riley FBR raised its rating on the $3.89 billion market cap company to a “Buy”, but maintained its target price of $58.0000 on YELP shares.

Heat Biologics Inc (HTBX) investors sentiment increased to 1 in 2017 Q4. It’s up 0.50, from 0.5 in 2017Q3. The ratio is better, as 4 funds started new and increased positions, while 4 decreased and sold stock positions in Heat Biologics Inc. The funds in our database now own: 3.62 million shares, up from 2.81 million shares in 2017Q3. Also, the number of funds holding Heat Biologics Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 3 Increased: 3 New Position: 1.

Yelp Inc. operates a platform that connects people with local businesses in the United States, Canada, and internationally. The company has market cap of $3.89 billion. The Company’s platform covers various local business categories, including restaurants, shopping, beauty and fitness, arts, entertainment and events, home and local services, health, nightlife, travel and hotel, auto, and others. It has a 26.54 P/E ratio. The firm provides free and paid business listing services to businesses, as well as enables businesses to deliver targeted search advertising to large local audiences through its Website and mobile application.

More notable recent Yelp Inc. (NYSE:YELP) news were published by: Seekingalpha.com which released: “Yelp: Upside Momentum Ahead” on May 19, 2018, also Seekingalpha.com with their article: “Yelp +3.4% as B. Riley boosts to Buy” published on May 18, 2018, Seekingalpha.com published: “Yelp: Another Dip Opportunity” on May 14, 2018. More interesting news about Yelp Inc. (NYSE:YELP) were released by: 247Wallst.com and their article: “What to Look For in Yelp Earnings” published on May 10, 2018 as well as Investorplace.com‘s news article titled: “Yelp Inc Stock Will Continue to Drop Thanks to Amazon, Facebook and Google” with publication date: May 15, 2018.

Analysts await Yelp Inc. (NYSE:YELP) to report earnings on August, 2. They expect $0.02 EPS, down 77.78% or $0.07 from last year’s $0.09 per share. YELP’s profit will be $1.67 million for 580.50 P/E if the $0.02 EPS becomes a reality. After $-0.03 actual EPS reported by Yelp Inc. for the previous quarter, Wall Street now forecasts -166.67% EPS growth.

Among 47 analysts covering Yelp (NYSE:YELP), 22 have Buy rating, 5 Sell and 20 Hold. Therefore 47% are positive. Yelp has $60 highest and $17 lowest target. $42.76’s average target is -7.92% below currents $46.44 stock price. Yelp had 160 analyst reports since July 28, 2015 according to SRatingsIntel. Mizuho maintained the stock with “Buy” rating in Wednesday, November 2 report. The firm has “Buy” rating given on Wednesday, August 10 by Mizuho. The stock of Yelp Inc. (NYSE:YELP) has “Buy” rating given on Wednesday, November 1 by SunTrust. On Wednesday, July 29 the stock rating was downgraded by Cowen & Co to “Market Perform”. As per Wednesday, July 29, the company rating was maintained by RBC Capital Markets. Stifel Nicolaus maintained it with “Hold” rating and $40 target in Friday, February 10 report. Axiom Capital upgraded the shares of YELP in report on Wednesday, August 10 to “Buy” rating. The firm has “Hold” rating by RBC Capital Markets given on Thursday, August 3. Jefferies maintained the stock with “Buy” rating in Thursday, November 2 report. The stock has “Hold” rating by Wells Fargo on Tuesday, July 25.

Since December 12, 2017, it had 0 insider purchases, and 30 selling transactions for $11.35 million activity. The insider Donaker Geoffrey L sold 6,000 shares worth $252,236. $550,130 worth of Yelp Inc. (NYSE:YELP) was sold by Stoppelman Jeremy. Another trade for 14,500 shares valued at $606,676 was sold by Nachman Joseph R.

Investors sentiment increased to 1.33 in Q4 2017. Its up 0.48, from 0.85 in 2017Q3. It is positive, as 37 investors sold Yelp Inc. shares while 49 reduced holdings. 44 funds opened positions while 70 raised stakes. 60.57 million shares or 0.90% more from 60.04 million shares in 2017Q3 were reported. Quantitative Systematic Strategies Limited has 0.18% invested in Yelp Inc. (NYSE:YELP). Aqr Capital Management Limited Com has invested 0.01% in Yelp Inc. (NYSE:YELP). Northern Corporation reported 0.01% stake. Eminence Ltd Partnership owns 2.07M shares. Caisse De Depot Et Placement Du Quebec holds 107,100 shares or 0.01% of its portfolio. 35,058 were reported by Legal And General Group Public Lc. Schwab Charles Mgmt invested 0.01% of its portfolio in Yelp Inc. (NYSE:YELP). Citigroup owns 36,699 shares. Millennium Ltd Company holds 0.03% of its portfolio in Yelp Inc. (NYSE:YELP) for 510,262 shares. Ameritas Partners Inc holds 6,820 shares or 0.01% of its portfolio. Trexquant Invest L P invested in 0.15% or 32,823 shares. 67,849 were accumulated by Bluemountain Limited. Moreover, Wells Fargo And Mn has 0% invested in Yelp Inc. (NYSE:YELP). Bnp Paribas Arbitrage Sa invested in 37,154 shares. Nine Masts Ltd reported 18,472 shares.

The stock increased 2.68% or $1.21 during the last trading session, reaching $46.44. About 2.43M shares traded or 88.77% up from the average. Yelp Inc. (NYSE:YELP) has risen 27.04% since May 20, 2017 and is uptrending. It has outperformed by 15.49% the S&P500.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company has market cap of $18.44 million. The firm develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. It currently has negative earnings. The Company’s product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer.

Sabby Management Llc holds 0.09% of its portfolio in Heat Biologics, Inc. for 2.62 million shares. Bank Of New York Mellon Corp owns 55,194 shares or 0% of their US portfolio. Moreover, Blackrock Inc. has 0% invested in the company for 7,030 shares. The North Carolina-based Franklin Street Advisors Inc Nc has invested 0% in the stock. Morgan Stanley, a New York-based fund reported 8,527 shares.

Another recent and important Heat Biologics, Inc. (NASDAQ:HTBX) news was published by Bizjournals.com which published an article titled: “This Durham company is $20M richer” on May 08, 2018.

Yelp Inc. (NYSE:YELP) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>